Physician profile
Daniel R Herdeman
NPI 1447293451
$613.55
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $16.18 · 2021: $16.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $134.59 | 2019 | |
| Pfizer INC. | $99.54 | 2019 | |
| Novo Nordisk INC | $85.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.47 | 2019 | |
| Amgen INC. | $58.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.13 | 2019 | |
| Amarin Pharma, INC. | $25.79 | 2019 | |
| Lilly USA, LLC | $24.63 | 2019 | |
| Merck Sharp & Dohme LLC | $22.70 | 2019 | |
| Abbott Laboratories | $16.18 | 2020 | |
| Esperion Therapeutics, INC. | $16.07 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.00 | 2019 | |
| Glaxosmithkline, LLC. | $12.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Herdeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.